Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

MLA

José Baselga, et al. Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the MTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....025a26d870c9fda45bccdde6460658d4&authtype=sso&custid=ns315887.

APA

José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, & Serena Di Cosimo. (2023). Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial.

Chicago

José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, et al. 2023. “Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the MTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....025a26d870c9fda45bccdde6460658d4&authtype=sso&custid=ns315887.